Nyt fra tidsskrifterne
Ingen søgeord valgt.
43 emner vises.
Lars Hviid, Nicaise Tuikue Ndam, Stephen J. Rogerson
Trends in Parasitology, 22.11.2024
Tilføjet 22.11.2024
Circumsporozoite protein-specific active and passive immunization can protect significantly against Plasmodium falciparum malaria and are being considered as tools to prevent placental malaria. Despite recent encouraging findings, a closer view of the underlying biology indicates significant challenges to preventing placental malaria.
Læs mere Tjek på PubMedThe Lancet
Lancet, 22.11.2024
Tilføjet 22.11.2024
The story of child and adolescent health over the past 25 years is one of clear but sometimes stalled progress, followed by the catastrophically negative impact of COVID-19, from which many children\'s lives have not recovered. It started with a focus on reducing mortality in children younger than 5 years, which almost halved, from 9·9 million deaths in 2000, to 5·3 million in 2019. It then expanded to include ensuring that children and adolescents fulfil their cognitive developmental potential through tackling poverty, providing nurturing care (ie, health, nutrition, responsive caregiving, safety and security, and early learning), and focusing on a life-course approach.
Læs mere Tjek på PubMedDerrick H Y Chong, Sylvia Pasternak, Trudy Taylor, Sam Armstrong, Kerri Purdy, Luke Y C Chen
Lancet, 22.11.2024
Tilføjet 22.11.2024
A 23-year-old woman with a 1-week history of a rash, fever, diffuse arthralgia, sore throat, and oral oedema attended our hospital. The patient had previously been fit and well; she had no medical history and was prescribed no medications.
Læs mere Tjek på PubMedWanyue Zhang Angela Sloan Jérémie Prévost Levi Tamming Sathya Raman Annabelle Pfeifle Caroline Gravel Wangxue Chen Anwar M. Hashem Jianguo Wu Jingxin Cao Michael J. W. Johnston Lisheng Wang Simon Sauve Michael Rosu-Myles Darwyn Kobasa David Safronetz Xuguang Li a Centre for Biologics Evaluation, Biologic and Radiopharmaceutical Drugs Directorate, HPFB, Health Canada and WHO Collaborating Center for Standardization and Evaluation of Biologicals, Ottawa, Canadab Department of Biochemistry, Microbiology and Immunology, Faculty of Medicine, University of Ottawa, Ottawa, Canadac National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canadad Human Health Therapeutics Research Center, National Research Council of Canada, Ottawa, Canadae Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabiaf Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabiag Department of Chemistry, Carlton University, Ottawa, Canada
Emerg Microbes Infect, 22.11.2024
Tilføjet 22.11.2024
Fereshteh Rostami-Maskopaee, Fani Ladomenou, Seyedeh-Kiana Razavi-Amoli, Mohammad Reza Navaeifar, Azin Hajialibeig, Leila Shahbaznejad, Fatemeh Hosseinzadeh, Behzad Haghighi Aski, Ali Manafi Anari, Mohsen Mohammadi, Mohammad Bagher Rahmati, Eslam Shorafa, Seyedenarjes Abootalebi, Mohammad Sadegh Rezai
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
by Fereshteh Rostami-Maskopaee, Fani Ladomenou, Seyedeh-Kiana Razavi-Amoli, Mohammad Reza Navaeifar, Azin Hajialibeig, Leila Shahbaznejad, Fatemeh Hosseinzadeh, Behzad Haghighi Aski, Ali Manafi Anari, Mohsen Mohammadi, Mohammad Bagher Rahmati, Eslam Shorafa, Seyedenarjes Abootalebi, Mohammad Sadegh Rezai
Læs mere Tjek på PubMedLida Esperanza Villa Castaño, William Fernando Durán, Paula Andrea Arohuanca Percca
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
by Lida Esperanza Villa Castaño, William Fernando Durán, Paula Andrea Arohuanca Percca
Læs mere Tjek på PubMedMaría Trujillo-Rodriguez, Esperanza Muñoz-Muela, Ana Serna-Gallego, Juan Manuel Praena-Fernández, Alberto Pérez-Gómez, Carmen Gasca-Capote, Joana Vitallé, Joaquim Peraire, Zaira R. Palacios-Baena, Jorge Julio Cabrera, Ezequiel Ruiz-Mateos, Eva Poveda, Luis Eduardo López-Cortés, Anna Rull, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
by María Trujillo-Rodriguez, Esperanza Muñoz-Muela, Ana Serna-Gallego, Juan Manuel Praena-Fernández, Alberto Pérez-Gómez, Carmen Gasca-Capote, Joana Vitallé, Joaquim Peraire, Zaira R. Palacios-Baena, Jorge Julio Cabrera, Ezequiel Ruiz-Mateos, Eva Poveda, Luis Eduardo López-Cortés, Anna Rull, Alicia Gutierrez-Valencia, Luis Fernando López-Cortés
Læs mere Tjek på PubMedThe PLOS ONE Editors
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
The PLOS ONE Staff
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Olla Hamdan, Justin Z. Amarin, Molly Potter, Zaid Haddadin, Ahmad Yanis, Yanal Shawareb, Najwa Khuri-Bulos, Randa Haddadin, Natasha B. Halasa, Andrew J. Spieker
PLoS One Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
by Olla Hamdan, Justin Z. Amarin, Molly Potter, Zaid Haddadin, Ahmad Yanis, Yanal Shawareb, Najwa Khuri-Bulos, Randa Haddadin, Natasha B. Halasa, Andrew J. Spieker Background Influenza is associated with significant global morbidity and mortality, with vaccination being the primary preventive strategy. Despite recommendations, influenza vaccine uptake among healthcare providers (HCPs) remains suboptimal, especially in the Eastern Mediterranean. We aimed to assess the attitudes and practices of HCPs in Jordan regarding seasonal influenza vaccination and assess sources of variation thereof. Methods We conducted a cross-sectional survey study among a sample of HCPs practicing in Jordan (12/29/2020–04/26/2021). Participants completed a questionnaire assessing demographics, influenza vaccination history, attitudes, and practices. We used logistic regression to evaluate factors related to vaccine receipt and reasons for non-vaccination. We used proportional odds models to evaluate factors related to HCP recommendations and to compare opinions on influenza vaccination between ever- and never-vaccinated HCPs. Results Of 305 survey initiates, 206 HCPs (67.5%) comprised the analytic sample. The median age was 35 years; 61.2% were women, and 43.7% were pharmacists. Over half (52.9%) never received an influenza vaccine; however, older age and self-identifying as a physician were associated with higher odds of having ever received the influenza vaccine. The main reasons for non-vaccination were related to the misassessment of risks and benefits. Prior receipt of influenza vaccination was strongly associated with odds of recommending vaccination (or = 10.5; 95% CI = [5.38–20.3]; p
Læs mere Tjek på PubMedOlivia A.C. Lamers, Blandine M.D. Franke-Fayard, Jan Pieter R. Koopman, Geert V.T. Roozen, Jacqueline J. Janse, Severine C. Chevalley-Maurel, Fiona J.A. Geurten, Helena M. de Bes-Roeleveld, Eva Iliopoulou, Emil Colstrup, Els Wessels, Geert-Jan van Gemert, Marga van de Vegte-Bolmer, Wouter Graumans, Thabitha R. Stoter, Benjamin G. Mordmüller, Emma L. Houlder, Teun Bousema, Rajagopal Murugan, Matthew B.B. McCall, Chris J. Janse, and Meta RoestenbergFrom Leiden University Center for Infectious Diseases, Leiden University Medical Center, Leiden (O.A.C.L., B.M.D.F-.F., J.P.R.K., G.V.T.R., J.J.J., S.C.C.-M., F.J.A.G., H.M.B.-R., E.I., E.C., E.W., E.L.H., R.M., C.J.J., M.R.), and the Department of Medical Microbiology, Radboud University Medical Center, Nijmegen (G.-J.G., M.V.-B., W.G., T.R.S., B.G.M., T.B., M.B.B.M.) — both in the Netherlands.
New England Journal of Medicine, 21.11.2024
Tilføjet 21.11.2024
New England Journal of Medicine, Volume 391, Issue 20, Page 1913-1923, November 21, 2024.
Læs mere Tjek på PubMedC. Corey HardinMichail S. Lionakis, and Anuradha ChowdharyFrom the Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD (M.S.L.); and the Medical Mycology Unit, Department of Microbiology, and the National Reference Laboratory for Antimicrobial Resistance in Fungal Pathogens, Vallabhbhai Patel Chest Institute, University of Delhi, Delhi, India (A.C.).
New England Journal of Medicine, 21.11.2024
Tilføjet 21.11.2024
New England Journal of Medicine, Volume 391, Issue 20, Page 1924-1935, November 21, 2024.
Læs mere Tjek på PubMedChristian Olivo-FreitesRyan Health, New York, NYPatricia Miguez-ArosemenaIcahn School of Medicine at Mount Sinai, New York, NYCristina Olivo-FreitesUniversity of Texas Health Science Center, Houston, TXDeborah EdelmanIcahn School of Medicine at Mount Sinai, New York, NYKayla Leschly, and Jayme LeschlyRyan Health, New York, NYLouise C. Ivers, and Amir M. MoharebMassachusetts General Hospital, Boston, MA amohareb@mgh.harvard.edu
New England Journal of Medicine, 21.11.2024
Tilføjet 21.11.2024
New England Journal of Medicine, Volume 391, Issue 20, Page 1959-1960, November 21, 2024.
Læs mere Tjek på PubMed*
New England Journal of Medicine, 21.11.2024
Tilføjet 21.11.2024
Jean Pierre SibomanaFrom King Faisal Hospital and the Department of Medicine, College of Medicine and Health Sciences, University of Rwanda — both in Kigali, Rwanda.
New England Journal of Medicine, 21.11.2024
Tilføjet 21.11.2024
Malaria Journal, 21.11.2024
Tilføjet 21.11.2024
Malaria Journal, 21.11.2024
Tilføjet 21.11.2024
Abstract Background Gene drive-modified mosquitoes (GDMMs) have been promoted as one of the innovative technologies that may control and eliminate malaria and other mosquito-borne diseases. Several products are in early stages of development, targeting either population suppression or population modification of the mosquito vector. However, there is no direct experience of conducting risk assessment for environmental releases and subsequent policies regarding conditions for post-release. This study was carried out to gain additional insights on the possible post-release concerns that may arise, as they may inform future risk assessment and planning for deployment. Methods This study involved desktop reviews on post release monitoring experiences with previously released biological control products. Stakeholder consultations involving online surveys, and face to face workshop with experts from selected African countries from Eastern, Western, and Southern African regions was then carried out to establish post-release monitoring concerns for GDMMs. Results Review of genetic biocontrol technologies showed only limited lessons from post-release monitoring regimes with a focus largely limited to efficacy. For genetically modified organisms general surveillance and case-specific monitoring is expected in some of the regions. A number of post-release monitoring concerns in relation to the protection goals of human and animal health, biodiversity, and water quality were identified. Conclusion Based on established- protection goals, several post-release monitoring concerns have been identified. Subject to a rigorous risk assessment process for future GDMMs products, the concerns may then be prioritized for post-release monitoring.
Læs mere Tjek på PubMedMalaria Journal, 21.11.2024
Tilføjet 21.11.2024
Abstract Background Insecticide-treated nets (ITNs) are the most commonly deployed tools for controlling malaria transmission in sub-Saharan Africa. However, some reports associate multiple alternative uses of nets with poor disposal practices, prompting this study to assess existing alternative uses and disposal practices of old ITNs in Burkina Faso after four universal distribution campaigns. Methods A quantitative survey combined with qualitative data collection was used to describe existing alternative uses and disposal practices for old ITNs in households from selected study sites in the three climatic zones of Burkina Faso. A survey questionnaire was distributed to 3,780 participants, and 12 focus groups were held to elucidate responses regarding existing disposal practices and alternative uses of ITNs. Results Of the 3780 households surveyed, 87.4% (3,330) reported having disposed of their ITNs when they were no longer usable due to age or wear. The most commonly cited disposal methods included alternative uses (67.4%), disposal with other garbage (61.4%), and burying (9%). In addition, the most common alternative uses included fencing for crops and seedlings (51.8%); ropes for tying items (40.4%); animal protection fencing (17.8%); house fencing (16.8%); bed covers (13.3%) and curtains for doors or windows (12.6%). Furthermore, trends in ITNs disposal mechanisms and alternative uses differed between study sites in each climate zone. All these ITNs disposal mechanisms and the different types of alternative use of old ITNs were confirmed in the focus group discussions. Conclusion The findings underscore the need for comprehensive strategies to manage the disposal and repurposing of old ITNs in Burkina Faso. Addressing gaps in disposal guidelines, promoting safe and beneficial reuse practices, and actively involving communities in the decision-making process can help mitigate health risks associated with the improper disposal and repurposing of old insecticide-treated nets and improve the overall effectiveness of malaria control programmes. Through these efforts, both public health and environmental concerns can be addressed in a sustainable and collaborative manner.
Læs mere Tjek på PubMedMingxin ZhangXiaoqin LianYarou GaoLefang JiangZhuogang LiHaonan ZhangYue SuQun PengXulin Chen1Department of Immunology and Microbiology, Institute of Medical Microbiology, College of Life Science and Technology, Jinan University47885, Guangzhou, Guangdong, ChinaMiguel Angel Martinez
Antimicrobial Agents And Chemotherapy, 21.11.2024
Tilføjet 21.11.2024
Dereje A. NegatuWassihun Wedajo AragawTewodros T. GebresilaseSindhuja ParuchuriFirat KayaSung Jae ShinPeter SanderVéronique DartoisThomas Dick1Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA2Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa University37602, Addis Ababa, Ethiopia3Armauer Hansen Research Institute70605, Addis Ababa, Ethiopia4Institute of Biotechnology, Addis Ababa University37602, Addis Ababa, Ethiopia5Department of Microbiology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine37991, Seodaemun-gu, Seoul, South Korea6Institut für Medizinische Mikrobiologie, Universitat Zurich Institut fur Medizinische Mikrobiologie30990, Zürich, Switzerland7National Reference Center for Mycobacteria, Universitat Zurich Institut fur Medizinische Mikrobiologie30990, Zürich, Switzerland8Department of Medical Sciences, Hackensack Meridian School of Medicine576909, Nutley, New Jersey, USA9Department of Microbiology and Immunology, Georgetown University8368, Washington, DC, USAJared A. Silverman
Antimicrobial Agents And Chemotherapy, 21.11.2024
Tilføjet 21.11.2024
Infection, 21.11.2024
Tilføjet 21.11.2024
Abstract Background The JYNNEOS vaccine (two doses given 28 days apart) was recommended in the United States for people at high risk of exposure to monkeypox virus during the 2022 mpox outbreak. Our objective was to assess the safety of JYNNEOS using two complementary epidemiologic methods. Methods This observational cohort included patients of eight large integrated healthcare organizations who received JYNNEOS. Adverse events were identified using ICD-10 coded diagnoses assigned to medical visits. The first analysis used standardized incidence ratios (SIR) to compare the observed incidence of ten prespecified adverse events of special interest (AESI) during the 28 days after receipt of each dose of JYNNEOS to the expected incidence adjusted for several risk factors. The second analysis used tree-based data mining to identify temporal clustering of cases for more than 60,000 diagnoses and diagnosis groups within 70-days after JYNNEOS dose 1 administration. Results The SIR analysis included 53,583 adults who received JYNNEOS dose 1 and 38,206 who received dose 2. Males received 92% of the doses. There were no statistically significant elevated SIRs for any of the ten AESI. The tree-based data mining analysis included 36,912 vaccinees. Analysis of diagnoses in inpatient, emergency department, and outpatient settings identified statistically significant clusters of visits for rash and unspecified adverse effects. Conclusions No new or unexpected safety concerns were identified. AESI did not occur more frequently than expected by chance alone. Non-serious medically attended adverse events, such as rash, have been previously reported and occurred infrequently.
Læs mere Tjek på PubMedKyeongbin Baek, Dongbum Kim, Bo Min Kang, Jinsoo Kim, Atanas V. Demirev, Sangyi Lee, Minyoung Kim, Suyeon Kim, Sangkyu Park, Jin Il Kim, Man‐Seong Park, Younghee Lee, Hyung‐Joo Kwon
Journal of Medical Virology, 21.11.2024
Tilføjet 21.11.2024
Priyanka Bhateja, Xuefeng Liu, Sujith Baliga, Emile Gogineni, Sachin Jhawar, Darrion Mitchell, Sungjun Ma, Simeng Zhu, David Konieczkowski, Dukagjin Blakaj, Matthew Old, James Rocco, Marcelo Bonomi
Journal of Medical Virology, 21.11.2024
Tilføjet 21.11.2024
Helen M Chun, Sophia Osawe, Samuel Adams-Dabban, Jennifer Favaloro, Nnaemeka C Iriemenam, Emilio Dirlikov, Diana Martin, Kyle Milligan, Andrew Abutu, Olumide Okunoye, Mary Okoli, Olusola Akanbi, Oluwaseun Akinmulero, Rita Okonkwo, Oyewole Oyedele, Stacie Greby, Alash'le Abimiku, McPaul I.J. Okoye, Ray W. Shiraishi, Dickson Adegoke, Mustapha Bello, Felix Villeng, Item Inya Item, Simon Gabo, Ado Abubakar, Andrew Thomas, Temitope Olaleye, Samuel Awala, Felicia Nwatu, Blessing Ugboaja, Ifeanyi Udoh, Loveth Akayi, Joseph Dattijo, Tolulope Adenekan, Asmau Aminu-Alhaji, Ijeoma Ezeuko, Nigeria SARS-CoV-2 Serosurvey Among PLHIV Working Group, Nigeria SARS-CoV-2 Serosurvey Among PLHIV Working Group
International Journal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Nigeria, Africa\'s most populous country, and 6th largest country by population in the world [1], experienced at least four waves of COVID-19 infection from February 2020 to November 2023 [2]. An estimated 267,146 confirmed cases [3] and a cumulative 3,155 deaths were reported up to November 2, 2023.[4] COVID-19 cases peaked in late December 2021, with a positive COVID-19 test rate greater than 21·8% [4], and over 1,950 daily new confirmed COVID-19 cases. COVID-19 vaccination was introduced in Nigeria in March 2021.
Læs mere Tjek på PubMedClaudio F. Lanata, Giselle Soto, Ana I. Gil, Joan Neyra, Rubelio Cornejo, Candice Romero, Lucie Ecker, Maria L. Huaylinos, Sayda La Rosa, Ana Goios, Astrid Borkowski, John Weil
International Journal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Acute gastroenteritis (AGE) is one of the leading causes of death in children under the age of 5 years. In this pediatric age group, noroviruses are estimated to cause 200 million annual AGE cases worldwide [1]. With widespread vaccination against rotavirus, norovirus has become the predominant cause of childhood AGE in several Latin American countries such as Peru [2]. A recent systematic review and meta-analysis found noroviruses to be associated with 15% of all AGE cases in Latin America [3], complementing the prevalence reported worldwide (18% of AGE cases) and in low- and middle-income countries (15%) [4,5].
Læs mere Tjek på PubMedJournal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Journal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Journal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Chlamydia psittaci is a zoonotic pathogen known to cause respiratory diseases in humans. Chlamydia infections are closely associated with apoptosis, in which miRNAs play regulatory roles. Herein, we demonstrated that C. psittaci infection induces apoptosis in human bronchial epithelial (HBE) cells and investigated regulatory mechanism involving miR-124-3p and the PI3K/AKT signaling pathway. Following C. psittaci infection in HBE cells, we observed an elevated of HBE cells apoptosis, accompanied by upregulation of miR-124-3p levels. Mechanistically, we identified EIF3B as a novel target gene of miR-124-3p, supported by the inverse correlation of their mRNA expressions. MiR-124-3p inhibitors reduced apoptosis induced by C. psittaci, increased the replication of C. psittaci and inhibited the PI3K/AKT activated, whereas miR-124-3p mimics produced opposite effects, and transfection with EIF3B siRNA reversed the effects of miR-124-3p inhibitors. Our findings suggest that miR-124-3p targeting EIF3B promotes apoptosis in C. psittaci-infected HBE cells through the activation of PI3K/AKT signaling pathway.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Background The persistence of latently infected cells prevents a cure of HIV. The intestinal mucosa contains numerous target cells, and high levels of HIV-1 DNA persist in this compartment under ART. While CD4+ T cells are the best characterized reservoir of HIV-1, the role of long-lived intestinal macrophages in HIV-1 persistence on ART remains controversial.Methods We collected duodenal and colonic biopsies from 12 people living with HIV (PLWH) on suppressive ART, enrolled in the ARNS EP61 GALT study. Total, integrated, intact and defective HIV-1 proviruses were quantified from sorted T cells and monocytes/macrophages. HIV-1 env quasispecies were analyzed by single-molecule next-generation sequencing and env-pseudotyped viruses were constructed to assess macrophage versus T-tropism.Results Total HIV-1 DNA levels in intestinal T cells were significantly higher than those in monocytes/macrophages (P
Læs mere Tjek på PubMedJournal of Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Tuberculosis (TB) necrotic granulomas contain triglyceride-rich macrophages (foam cells) with reduced antimicrobial functions. We assessed the ability of two compounds to reduce triglyceride content and Mycobacterium tuberculosis (Mtb) burden in infected human monocyte-derived macrophages and in the lungs of Mtb-infected C3HeB/FeJ mice: A-922500 (DGATi), an inhibitor of diacylglycerol acyltransferase 1; and LY2584702 (p70S6Ki), an inhibitor of p70 S6 kinase. DGATi and p70S6Ki significantly reduced the lipid content and bacillary burden in Mtb-infected macrophages. Each inhibitor reduced the cellular triglyceride content in bronchoalveolar lavage samples of Mtb-infected mice. After 6 weeks of treatment, p70S6Ki alone reduced the lung bacterial burden in Mtb-infected mice. However, DGATi alone, and DGATi or p70S6Ki in combination with isoniazid did not reduce lung bacterial burden or alter lung inflammation. These findings provide further insight into the role of foam cells in tuberculosis pathogenesis and the utility of interventions targeting these cell populations as adjunctive host-directed therapies.
Læs mere Tjek på PubMedAnna L. Goodman, Gerard Lina, Ed J. Kuijper
Clinical Microbiology and Infection, 21.11.2024
Tilføjet 21.11.2024
Community-onset meticillin-resistant Staphylococcus aureus (MRSA) (CO-MRSA) has been under recognised and under described outside the USA and we welcome this themed issue comprising 4 narrative reviews on the topic which cover a wide range of issues.
Læs mere Tjek på PubMedYehoshua, I., Baruch Gez, S., Cohen, B., Hemo, B., Irony, A., Abou Houssien, K., Shental, O., Shapiro Ben David, S., Adler, L.
BMJ Open, 21.11.2024
Tilføjet 21.11.2024
ObjectivesThis study aims to evaluate and compare health outcomes and costs between home hospitalisation and traditional hospitalisation for three common diagnoses—cellulitis, urinary tract infection (UTI) and pneumonia. DesignA retrospective cohort study. SettingPrimary care, nationwide. Participants1311 patients in home hospitalisation and 992 in traditional hospitalisation. InterventionsThe primary intervention is home hospitalisation, compared with traditional hospitalisation. The intervention was performed according to medical considerations by a specialised team, and this study was done retrospectively to evaluate it. Primary and secondary outcome measuresPrimary measures included healthcare costs, length of hospitalisation, referrals for further medical services and mortality. ResultsCosts of home hospitalisation were lower compared with traditional hospitalisation (6056 vs 9619 NIS for pneumonia, 6011 vs 9767 NIS for cellulitis, 6466 vs 8552 NIS for UTI and p value
Læs mere Tjek på PubMedArkell, P., Ketklao, S., Songjaeng, A., Mairiang, D., Rodriguez-Manzano, J., Georgiou, P., Holmes, A., Ahmad, R., Malasit, P., Avirutnan, P., Lawpoolsri, S.
BMJ Open, 21.11.2024
Tilføjet 21.11.2024
ObjectivesEffective, real-time surveillance of dengue may provide early warning of outbreaks and support targeted disease-control intervention but requires widespread accurate diagnosis and timely case reporting. Research directing innovation in diagnostics for dengue surveillance is lacking. This study aimed to describe experience and requirements of relevant prospective users. DesignA qualitative, focus group study was conducted. ParticipantsData were collected from 19 users of diagnostic technology who work across the Thai dengue surveillance system. Data collection and analysisContextual knowledge, experience and needs were explored in focus groups. Discussions were translated, transcribed, analysed thematically and mapped to Consolidated Framework for Implementation Research domains. ResultsParticipants expressed a need for rapid, accurate, serotype-specific tests which can be operated easily by non-expert users without laboratory equipment. They supported integration of diagnostics with surveillance systems and felt this would increase the quantity and speed of case reporting as well as provide healthcare professionals with up-to-date information about the number of cases locally, thereby aiding interpretation of test results. Concerns included those relating to data security and the cost of tests. ConclusionsEngagement to understand prospective user experience and requirements can improve relevance and uptake of new technology, leading to system efficiencies. The present study highlights specific needs for accurate, serotype-specific, remote-connected diagnostics which are integrated with surveillance systems and support dengue case reporting at the point-of-care.
Læs mere Tjek på PubMedHurley, J.
BMJ Open, 21.11.2024
Tilføjet 21.11.2024
ObjectiveTo estimate the herd effects of anti-microbial-based decontamination (ABD) interventions on bloodstream infections (BSIs) among groups of intensive care unit (ICU) patients in relation to group mean length of stay (LOS). To deduce which of three competing hypotheses of ABD effect mediation best accounts for the observed effects. DesignArms-based meta-regression of ICU-acquired BSI incidence against group mean LOS for control and interventions arms of ABD and non-ABD controlled trials each versus that in arms of observational studies. ExposuresWithin controlled trials of ABD, intervention, concurrent control (CC) and non-concurrent (NCC) groups are directly, indirectly and non-exposed, respectively. Main outcomes and measuresBSI incidence, both overall and for BSI subtypes. ResultsIn the arms-based meta-regression, the predicted BSI incidence per 100 patients in the ABD intervention arms increased from 4.6 (95% CI 3.8 to 5.5) at mean LOS 7 days to 13.0 (10.4–16.0) at mean LOS 20 days (n=60 arms) and CC arms 8.5 (6.7–11.0) increasing to 19.3 (14.8–24.8; n=52). These increases were double those in the observational (7.2; 6.1–8.5 increasing to 12.9; 10.4–16.7; n=99) and NCC arms and non-ABD arms. These results triangulate with the notional effect size observed in contrast-based meta-analyses. ConclusionsThe increased tempo of BSI acquisition, both overall and for various BSI subtypes, within intervention and CC groups of ABD randomised concurrent controlled trials versus other groups implicate rebound and spillover, respectively. Mechanisms other than colonisation resistance mediate ABD effects.
Læs mere Tjek på PubMedBMC Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Background Common non-COVID respiratory viruses, such as influenza virus (IFVA/IFVB), parainfluenza virus (PIV), respiratory syncytial virus (RSV), and adenovirus (ADV), often cause acute respiratory infections (ARIs). This study aimed to explore the epidemiological characteristics of these five viruses in patients with ARIs before, during, and after the COVID-19 pandemic from 2018 to 2023. Methods A total of 37,139 serum specimens and epidemiological data from all-aged patients who presented with ARIs were collected from January 2018 to December 2023. The IgM antibodies of five non-COVID respiratory viruses were tested by an IgM kit with indirect immunofluorescent assay (lFA). Results 12,806 specimens were screened as positive for any one of the targeted viruses, with an overall positivity rate of 34.48%. Among all age groups, the most prevalent respiratory viruses were PIV (21.30%) and influenza virus (17.30% of IFVB and 9.91% of IFVA). Children aged 1–14 years were most vulnerable to lower respiratory viruses, and children aged 4–6 years have the highest prevalence no matter the positivity rate for overall viruses (53.06%) or for each virus. From 2018 to 2023, the annual percentage change (APC) revealed that the prevalence of total viruses have a 13.53% rise (p 60 years) were all the highest in 2023, and the number of samples collected in 2023 sharply increased, increasing by 77.10% compared to the average of the number of detected in 2018–2022. Conclusions The data from this study indicate that the epidemiological characteristics of five non-COVID respiratory viruses are vulnerability to the environment, age, sex, and epidemics status among AIR patients, and that the detected number and positivity rate of these viruses have increased in the “post-pandemic era”, which is critical for the late or retrospective diagnosis and can serve as a useful surveillance tool to inform local public policy in Weifang, China.
Læs mere Tjek på PubMedBMC Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Background The HIV epidemic in Kenya remains a significant public health concern, particularly among gay, bisexual, and other men who have sex with men (GBMSM), who continue to bear a disproportionate burden of the epidemic. This study’s objective is to describe HIV phylogenetic clusters among different subgroups of Kenyan GBMSM, including those who use physical hotspots, virtual spaces, or a combination of both to find male sexual partners. Methods Dried blood spots (DBS) were collected from GBMSM in Kisumu, Mombasa, and Kiambu counties, Kenya, in 2019 (baseline) and 2020 (endline). HIV pol sequencing was attempted on all seropositive DBS. HIV phylogenetic clusters were inferred using a patristic distance cutoff of ≤ 0.02 nucleotide substitutions per site. We used descriptive statistics to analyze sociodemographic characteristics and risk behaviors stratified by clustering status. Results Of the 2,450 participants (baseline and endline), 453 (18.5%) were living with HIV. Only a small proportion of seropositive DBS specimens were successfully sequenced (n = 36/453; 7.9%), likely due to most study participants being virally suppressed (87.4%). Among these sequences, 13 (36.1%) formed eight distinct clusters comprised of seven dyads and one triad. The clusters mainly consisted of GBMSM seeking partners online (n = 10/13; 76.9%) and who tested less frequently than recommended by Kenyan guidelines (n = 11/13; 84.6%). Conclusions Our study identified HIV phylogenetic clusters among Kenyan GBMSM who predominantly seek sexual partners online and test infrequently. These findings highlight potential unmet HIV prevention, testing, and treatment needs within this population. Furthermore, these results underscore the importance of tailoring HIV programs to address the diverse needs of GBMSM in Kenya across different venues, including both physical hotspots and online platforms, to ensure comprehensive prevention and care strategies.
Læs mere Tjek på PubMedBMC Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Background Commercial insurance claims data are a stable and consistent source of information on Lyme disease diagnoses in the United States and can contribute to our understanding of overall disease burden and the tracking of epidemiological trends. Algorithms consisting of diagnosis codes and antimicrobial treatment information have been used to identify Lyme disease diagnoses in claims data, but there might be opportunity to improve their accuracy. Methods We developed three modified versions of our existing claims-based Lyme disease algorithm; each reflected refined criteria regarding antimicrobials prescribed and/or maximum days between diagnosis code and qualifying prescription claim. We applied each to a large national commercial claims database to identify Lyme disease diagnoses during 2016–2019. We then compared characteristics of Lyme disease diagnoses identified by each of the modified algorithms to those identified by our original algorithm to assess differences from expected trends in demographics, seasonality, and geography. Results Observed differences in characteristics of patients with diagnoses identified by the three modified algorithms and our original algorithm were minimal, and differences in age and sex, in particular, were small enough that they could have been due to chance. However, one modified algorithm resulted in proportionally more diagnoses in men, during peak summer months, and in high-incidence jurisdictions, more closely reflecting epidemiological trends documented through public health surveillance. This algorithm limited treatment to only first-line recommended antimicrobials and shortened the timeframe between a Lyme disease diagnosis code and qualifying prescription claim. Conclusions As compared to our original algorithm, a modified algorithm that limits the antimicrobials prescribed and shortens the timeframe between a diagnosis code and a qualifying prescription claim might more accurately identify Lyme disease diagnoses when utilizing insurance claims data for supplementary, routine identification and monitoring of Lyme disease diagnoses.
Læs mere Tjek på PubMedBMC Infectious Diseases, 21.11.2024
Tilføjet 21.11.2024
Abstract Background Brucellosis poses a significant public health challenge in China. Inner Mongolia, characterized by its developed livestock industry, is the most severe endemic area for human brucellosis. This study aims to describe the epidemiology, explore the spatial–temporal distribution patterns, and clustering characteristics of human brucellosis in Inner Mongolia. Methods Data on human brucellosis cases from 2010 to 2021 were obtained from the Centers for Disease Control and Prevention in Inner Mongolia. Spatial autocorrelation analysis was used to identify high-risk areas, while spatial–temporal scan statistics were employed to detect changes in clusters over time. Results A total of 153,792 brucellosis cases were reported in Inner Mongolia from 2010 to 2021, with an average annual incidence rate of 52.59 per 100,000 persons. The incidence showed a decreasing trend from 2010 to 2016, followed by a significant increase from 2016 to 2021. The disease exhibited distinct seasonality, peaking in spring and summer (March to August). Middle-aged individuals, males, and farmers/herdsmen had higher incidence rates. Spatially, incidence rates decreased from north to south and from the central and eastern regions to the west. Clear spatial clusters were observed during 2010–2013 and 2016–2021 in the global Moran’s I test. Local spatial autocorrelation analysis revealed that high-high clusters expanded from the central and eastern regions towards the west over time. Spatio-temporal scan analysis further indicated that high-risk clusters were primarily concentrated in the central and eastern regions, with a continuous expansion towards the west and south, leading to an increasingly broad geographical spread. Conclusion Human brucellosis cases in Inner Mongolia exhibit spatio-temporal clustering, with spatial concentration in the central and eastern regions, but also observed expansion towards the western and southern regions. The most of cases occur between March and August each year. For high-risk areas and populations, more timely and effective prevention and control measures should be implemented to mitigate the spread of brucellosis and protect public health.
Læs mere Tjek på PubMedYuanyuan Wang Dalin He Weihua Li Yaqin Dong Linlin Fang Deju Liu Yi Tang Shaobo Xiao a College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, Chinab College of Veterinary Medicine, Shandong Agricultural University, Tai’an, Chinac Department of Animal Health Standards and Regulation, China Animal Health and Epidemiology Center, Qingdao 266000, Shandong Province,China
Virulence, 21.11.2024
Tilføjet 21.11.2024
Reese Jalal LadakJung-Hyun ChoiJun LuoOwen J. ChenNiaz MahmoodAlexander J. HeParisa NaeliPatric Harris SnellEsha BayaniHuy-Dung HoangTommy AlainJose G. TeodoroJianwei WangXu ZhangSeyed Mehdi JafarnejadNahum SonenbergaDepartment of Biochemistry, Rosalind and Morris Goodman Cancer Institute, McGill University, Montreal, QC H3A 1A3, CanadabDepartment of Physiology, McGill University, Montreal, QC H3A 1A2, CanadacPatrick G. Johnston Centre for Cancer Research, Queen’s University Belfast, Belfast BT9 7AE, United KingdomdDepartment of Ophthalmology and Visual Sciences, McGill University, Montreal, QC H3A 2B4, CanadaeDepartment of Biochemistry, Microbiology and Immunology, Faculty of Medicine, Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON K1H 8L1, CanadafCenter of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
Proceedings of the National Academy of Sciences: Immunology and Inflammation, 21.11.2024
Tilføjet 21.11.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 48, November 2024.
Læs mere Tjek på PubMedYan, Lily D.; Rouzier, Vanessa; Sufra, Rodney; Sauveur, Reichling S.T.; Guiteau, Colette; Lee, Myung Hee; Ogyu, Anju; Mourra, Nour; Oparil, Suzanne; Théard, Michel; Brisma, Jean Pierre; Alfred, Jean Patrick; Deschamps, Marie D.; Pape, Jean W.; Mcnairy, Margaret L.
AIDS, 21.11.2024
Tilføjet 21.11.2024
Objective: Elevated blood pressure (BP), even at prehypertensive levels, increases cardiovascular disease risk among people with HIV (PWH); yet international guidelines in low-income countries recommend treatment initiation at BP at least 140/90 mmHg. We determined the efficacy, feasibility, and acceptability of treating prehypertension in PWH in Haiti. Design: An unblinded randomized clinical trial (enrolled April 2021–March 2022) with 12-month follow-up. Setting: GHESKIO Centres, Port-au-Prince, Haiti. Participants: Two hundred fifty adults with HIV with prehypertension (SBP 120–138 or DBP 80–89) not on medication, aged 18–65 years, virally suppressed, and without pregnancy, diabetes, or kidney disease. Intervention: Participants were randomized to treatment (amlodipine 5 mg) or control (no amlodipine unless two BP ≥140/90 mmHg). Main outcome measure: Primary outcome was mean change in SBP between intervention versus control groups from enrollment to 12 months. Results: Among 250 adults, median age was 49 years, 40.8% were women. Baseline median BP was 129/78 mmHg intervention versus 128/77 mmHg control. After 12 months, the difference in mean change between study groups for SBP was -5.9 mmHg [95% confidence interval (95% CI) -8.8 to -3.0] and for DBP was -5.5 mmHg (95% CI -7.9 to -3.2). At 12 months, 5.6% intervention and 23.0% control participants developed incident hypertension (hazard ratio 0.18; 95% CI 0.07–0.47). There were no differences in viral load suppression at 12 months or drug-related serious adverse events. Intervention acceptability was high among providers and participants in qualitative interviews. Conclusion: In PWH in a resource-poor setting, prehypertension treatment was feasible, acceptable, and effective in reducing mean SBP and incident hypertension. Registration: Clinicaltrials.gov NCT04692467 JOURNAL/aids/04.03/00002030-990000000-00587/figure1/v/2024-11-13T090640Z/r/image-jpeg Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Læs mere Tjek på PubMeddos Santos, Andre P.; Willig, Amanda L.; Ruderman, Stephanie; Oliveira, Vitor H.F.; Davey, Christine Horvat; Buford, Thomas W.; Long, Dustin M.; Gripshover, Barbara; Katundu, Mari; Cleveland, John D.; Crane, Heidi M.; Fleming, Julia; Burkholder, Greer; Saag, Michael S.; Webel, Allison R.
AIDS, 21.11.2024
Tilføjet 21.11.2024
Objective: Falls are a significant public health concern, particularly among older adults and people with HIV (PWH). This study examines the association between alcohol consumption and falls in PWH. Methods: The PROSPER-HIV study recruited PWH from four US sites. Participants were categorized based on Alcohol Use Disorders Identification Test Consumption (AUDIT-C) scores: none, non-hazardous, and hazardous drinking. Data collection included demographics, medical history (i.e., comorbidities, treated hypertension, eGFR), alcohol consumption using AUDIT-C, daily alcohol recall in grams, and self-reported falls over the previous year. Physical performance was measured using the Short Performance Physical Battery (SPPB). Statistical analyses included Pearson\'s correlation and Poisson regression models to estimate fall prevalence ratios (PR), adjusting for confounders (SPPB, comorbidities, treated hypertension, and eGFR). Results: The study included 315 PWH, aged 52 ± 12 years, with 78% male participants. Thirty-three percent were classified as non-drinking, 50% non-hazardous, and 17% hazardous drinking. Poisson regression showed a significantly higher risk of falls (PR: 2.12, 95% CI: 1.11–4.03) and recurrent falls (PR: 3.54, 95% CI: 1.21–10.3) among hazardous drinking compared to non-hazardous drinking, even after adjusting for confounders. The PR for falls per daily intake in grams was not statistically significant. Conclusions: There is a significant association between hazardous alcohol consumption and increased fall risk in PWH using AUDIT-C, but not when accessing recall of alcohol consumption in grams. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere Tjek på PubMedNovitsky, Vlad; Steingrimsson, Jon; Guang, August; Dunn, Casey W.; Howison, Mark; Gillani, Fizza S.; Hague, Joel; Fulton, John; Bertrand, Thomas; Bhattarai, Lila; MacAskill, Meghan; Bandy, Utpala; Hogan, Joseph; Kantor, Rami
AIDS, 21.11.2024
Tilføjet 21.11.2024
Background : Characterizing HIV clustering rates and their trends over time can improve understanding a local epidemic and enhance its control. Methods: Leveraging an academic-public health partnership in Rhode-Island, we explored longitudinal dynamics of statewide clustering rates among key populations from 1991 to 2023. Partial HIV-1 pol sequences were grouped by year of HIV-1 diagnosis. Molecular clusters were identified in cumulative annual phylogenies. Overall clustering rates, and clustering rates of newly-diagnosed and prevalent infections, and of specific socio-demographic characteristics of key populations over time were determined. Mann-Kendall statistics were used to estimate clustering rate trends and relationships among groups. Results: By the end of 2023, 2,630 individuals with sequences represented the statewide epidemic in Rhode Island. Overall clustering rates increased from 7% in 1991 to 46% in 2023, correlating with cumulative sequence increase. Clustering rates of newly-diagnosed and prevalent infections significantly increased over time, higher in newly-diagnosed individuals since the early 2000 s. Increases were also observed among groups defined by gender, age, transmission risks, race, mental illness, HIV-1 subtypes, and country of birth, with some crossovers and divergence patterns over time. Conclusions: Exploring dynamics of HIV clustering rates over three decades in a statewide HIV-1 epidemic expanded its characterization and provided insight into its evolving changes. These dynamics may indicate a gradual shift towards a more concentrated and localized HIV-1 epidemic, highlighting important opportunities for targeted interventions to effectively prevent new HIV transmissions. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere Tjek på PubMed